Article
Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Scientific reports - 20 Dec 2019
Yonesaka Kimio, Iwama Eiji, Hayashi Hidetoshi, Suzuki Shinichiro, Kato Ryoji, Watanabe Satomi, Takahama Takayuki, Tanizaki Junko, Tanaka Kaoru, Takeda Masayuki, Sakai Kazuko, Azuma Koichi, Chiba Yasutaka, Atagi Shinji, Nishio Kazuto, Okamoto Isamu, Nakagawa Kazuhiko
Abstract excerpt
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are standard therapy for EGFR-mutant non-small cell lung cancer (NSCLC). Preclinically, HER3 ligand heregulin induces resistance to EGFR-TKIs, whereas the pan-human EGFR family inhibitor afatinib remains effective. Here, we examined whether soluble heregulin levels have clinical implications for EGFR-mutant NSCLC treated with EGFR-TKIs....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.